Influence of a 23S ribosomal RNA mutation in Helicobacter pylori strains on the in vitro synergistic effect of clarithromycin and amoxicillin by Türkan Sakinc et al.
Sakinc et al. BMC Research Notes 2012, 5:603
http://www.biomedcentral.com/1756-0500/5/603RESEARCH ARTICLE Open AccessInfluence of a 23S ribosomal RNA mutation in
Helicobacter pylori strains on the in vitro
synergistic effect of clarithromycin and amoxicillin
Türkan Sakinc1,2*, Barbara Baars2, Nicole Wüppenhorst3, Manfred Kist3, Johannes Huebner1
and Wolfgang Opferkuch2Abstract
Background: Clarithromycin (CLR) is the most commonly recommended antibiotic in Helicobacter pylori eradication
regimens, but the prevalence of CLR-resistant H. pylori is increasing. CLR resistance is associated with mutations in
the 23S rRNA gene. However, H. pylori eradication can still be achieved with triple therapy, and an additive effect
may occur with multiple antibiotics.
Methods: Twenty-six CLR-resistant strains were examined. The MIC of clarithromycin was determined by
agar-dilution-testing on Columbia agar, as described elsewhere. The conserved region of the H. pylori 23S rRNA
gene between nucleotide positions 1445 and 2846 [GenBank: U27270] was amplified. RFLP and sequence analysis
were performed with the 1402-bp PCR product. Synergy between clarithromycin and amoxicillin was assessed
using the agar dilution checkerboard technique. To confirm the correlation between mutation and synergistic effect
with subinhibitory concentrations of AMX, site-directed mutagenesis was performed in four CLR-susceptible
H. pylori isolates.
Results: Twenty-six clarithromycin-resistant strains were examined. The conserved region of the H. pylori 23S rRNA
gene was amplified, and the purified PCR product was checked for mutations by restriction fragment length
polymorphism (RFLP) analysis and sequencing. A synergistic effect was found in only three of the 12 H. pylori strains
(25%) with the A2142G mutation and five of the 10 H. pylori strains (50%) with the A2143G mutation (fractional
inhibitory concentration: FIC < 0.5, minimal inhibitory concentration: MIC<2 mg/L) was found. Site-directed
mutagenesis was performed in four CLR-susceptible H. pylori isolates.
Three of these isolates harboring a mutation in position A2143G grew under selection with CLR (MIC >16 mg/L),
and all three strains showed the synergistic effect (FIC<0.5). In contrast, three of the same four strains transformed
with DNA fragments with a mutation in position A2142G were resistant to CLR (MIC>16 mg/L) and showed no
synergism with amoxicillin (FIC>2).
Conclusions: Here we demonstrate that in 100% of the in vitro transformed strains, a mutation at position A2143G
leads to a synergistic effect between clarithromycin and amoxicillin, whereas a mutation at position at A2142G had
no discernible effect.
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Infection with H. pylori is the major cause of chronic
gastritis and peptic ulceration and an important factor in
the development of gastric cancer [1]. The introduction
of triple therapy (i.e., the combination of two antibio-
tics and a proton pump inhibitor) was a major advance
in the treatment of gastritis and peptic ulcer disease
[2,3]. However, the initial success of such therapy was
blunted by the emergence of resistance against the
first-line drugs clarithromycin (CLR) and metronidazole
(MTZ) [2,3].
The major cause of CLR resistance in H. pylori strains
is point mutations in domain V of the 23S ribosomal
RNA gene (A2142G, A2143G) [3,4]. An earlier publica-
tion identifies two different CLR-resistant populations:
one with an A2142G mutation and MIC values >16mg/L;
and the other with an A2143G mutation and MIC values
of 8-16mg/L [5].
Surprisingly, H. pylori eradication can still be achieved
with triple therapy (CLR, amoxicillin/AMX), and a pro-
ton pump inhibitor) even if the strain tests CLR- resist-
ant [6]. This points to a synergistic effect between CLR
and AMX. To study this synergism, we tested 26 CLR-
resistant H. pylori-strains [7] in vitro with the checker-
board method and subsequently correlated the results
with mutations in the 23S ribosomal RNA gene.Methods
Bacterial strains and media
Twenty-six clinical CLR-resistant isolates of H. pylori
were tested [7]. The strains were originally obtained
from gastric biopsy samples and were kindly provided by
B. Baars [7]. In addition, the following four CLR-
susceptible H. pylori strains were used for mutagenesis
and resistance experiments: strain CCUG 38772 (which
contains a mutation at position A2142G in the 23S
rRNA gene) and strain 30K 184 (with a mutation at pos-
ition A2143G) were obtained from the German national
reference centre for H. pylori (Freiburg, Germany) and
used as control strains. Brain heart infusion bouillon
(BHI, Oxoid CM225), supplemented with 1% hemin and
10% horse serum, was used for liquid culture, whereas
columbia agar (Oxoid CM 331) supplemented with 10%
sheep- blood (Oxoid FSR 1055) was used as solid
medium.Susceptibility testing
The MIC of clarithromycin was determined by agar-
dilution-testing on Columbia agar, as described else-
where. The plates were incubated at 37°C under micro-
aerophilic conditions (i.e., 5% CO2) for 5–7 d. Bacterial
strains were classified as clarithromycin resistant if the
MIC was ≥1 mg/L.Synergy testing
Synergy between clarithromycin and amoxicillin was
assessed using the agar dilution checkerboard technique.
For quantitation of synergism, the fractional inhibitory
concentration (FIC) indices for both combinations were
calculated as described by Eliopoulos et al. [8]. The
ranges used for description of the FIC indices were as
follows: <0.5, synergy; > 0.5 to 1, additive; >1 to 4, indif-
ference; >4, antagonism.
DNA isolation and PCR of 23S rRNA gene
Genomic DNA was isolated using the QIAamp DNA
mini kit (Qiagen, Hilden, Germany) according to the
manufacturer0s instructions. The conserved region of the
H. pylori 23S rRNA gene between nucleotide positions
1445 and 2846 [GenBank: U27270] was amplified using for-
ward primer 50- AGTCGGGGACCTAAGGCGAG - 30-
and reverse primer 50 - TTCCCGCTTAGATGCTTTCAG- 30
with the genomic DNA of 26 CLR-resistant H. pylori
isolates serving as a template [5].
RLFP analysis
RFLP analysis was performed with the 1402-bp PCR
product obtained as described above. To detect the A-
to-G point mutation at nucleotide position 2142, the
DNA was digested with restriction enzymes BbsI, and
for detection of the mutation at position 2143, digestion
with BsaI was used. The resulting DNA fragments were
then analyzed by electrophoresis on 0.8% agarose gels.
DNA sequencing and sequence analysis
PCR fragments were purified using the QIAqiuck PCR
Purification Kit (Qiagen, Hilden, Germany). Sequencing
was performed using the BigDye Terminator v3.1 se-
quencing kit and analyzed on an ABI PRISM 377 Gen-
etic Analyzer. The sequences were analyzed using free
ClustalW software.
Site-directed mutagenesis
To construct an A2142G mutation, fragments were ampli-
fied with primer pairs DP1 (50ACGGCGGCCGTAAC
TATA 30) /GW11 (50GGTCTTCCCGTCTTGCCGC 30)
and ZGE23 (50ACAGGCCAGTTAGCTA 30) /GW1
(50GACGGGAAGACCCCGTGGA 30), and for A2143G,
mutation fragments were amplified with primer pairs
DP1/GW14 (50GGTCTCTCCGTCTTGCCGC 30) and
ZGE23 /GW4 (50GACGGAGAGACCCCGTGGA 30) as
described by Ge and Taylor [5]. The final 307-bp frag-
ments of all four strains were confirmed by nucleotide se-
quencing and then introduced into the CLR-susceptible
H. pylori isolates by natural transformation as described
previously [5]. Grown colonies (transformants) on CLR
agar plates after four days were confirmed for successful
transformation and mutation by PCR, followed by DNA
Table 2 In vitro site-directed mutagenesis of H. pylori 23S
rRNA gene and geno- and phenotypes of the
mutants obtained
No. of Donor DNA No. of Final No. of FIC
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was isolated to control RNA expression and mutation in
















4 A2142G 3 (A2142G) >16 0 (0%) >2
A2143G 3 (A2143G) >16 3 (100%) <0.5Results and discussion
Twenty-six CLR-resistant strains were examined by
RLFP (data not shown) and sequencing. This analysis
revealed that 12 of the H. pylori isolates carried the
A2142G mutation, and an additional 10 H. pylori isolates
harbored the A2143G mutation (Table 1). Four CLR-
resistant H. pylori isolates did not display any mutation.
Only three of the 12 H. pylori strains (25%) with the
A2142G mutation and five of ten H. pylori strains (50%)
with the A2143G mutation showed a synergistic effect
(FIC < 0.5, MIC<2 mg/L) with subinhibitory concentra-
tions of AMX. These results suggest that the synergistic
effect might also depend on the mutation at position
A2143G in the 23S rRNA gene.
To confirm the correlation between mutation and syn-
ergistic effect with subinhibitory concentrations of
AMX, site-directed mutagenesis was performed in four
CLR-susceptible H. pylori isolates. Each point mutation
at position A2142G or A2143G of the H. pylori 23S
rRNA gene was generated by a sequential PCR method
[5] using genomic DNA from four CLR-susceptible H.
pylori strains as a template for each amplification. The
obtained transformants were controlled/verified for
point mutation as described under 'Methods'.
As shown in Table 2, three of four strains transformed
with DNA fragments harboring a mutation in position
A2143G grew under selection with CLR (MIC >16 mg/L).
All three strains showed a synergistic effect (FIC<0.5)
when combined with subinhibitory concentrations of
AMX. In contrast, though three of four strains trans-
formed with DNA fragments including a mutation in pos-
ition A2142G did grow with CLR (MIC>16 mg/L), they
showed no synergistic effects (FIC>2). One of the four
strains was not transformable with either of the two point
mutations. These results confirm our assumption that a
point mutation in position A2143G may lead to a syner-
gistic effect for AMX and CLR in H. pylori in vitro experi-
ments. In other words, a point mutation at position
A2142G interferes with or suppresses the synergism.Table 1 Summary of checkerboard results: 26 H. pylori
strains tested with clarithromycin versus amoxicillin
correlated to mutations in 23S rRNA
Mutation in 23S
rRNA gene
No. of strains Synergy (FIC < 0.5) MIC
A2143G 10 5 (50%) <2
A2142G 12 3 (25%) >16
FIC: fractional inhibitory concentration [8].Additional experiments have been carried out with the
same four CLR-susceptible H. pylori-strains used for mu-
tagenesis by incubating them with subinhibitory concen-
trations of CLR. The MIC increased in these strains to
>16mg/L after not more than four passages, but no muta-
tion at the described positions of the 23S rRNA gene
could be found, and interestingly, they also demonstrated
no synergism. This result clearly confirmed our hypoth-
esis. Accordingly, our data strongly suggest that a muta-
tion at position A2143G may leads to a synergism
between AMX and CLR in vitro. Furthermore, these
results also demonstrate that different mechanisms are re-
sponsible for the CLR resistance.
The mutation at A2143G in the 23S rRNA is frequently
found in several countries: e.g., Spain 79.4%, Brazil 74%,
and Tunisia 88% [9]. It is the dominant mutation in
macrolide-resistant strains of H. pylori. Besides the resist-
ance loci A2142G and A2143G, several other less frequent
resistance loci have been described, such as 23S rRNA
mutations at positions 2058 and 2059, which are found in
various geographic locations (including Japan) but have
not yet been detected in European H. pylori isolates [10].
Mutation at T2182C was found in 5.9% of isolates in
Spain [9]. It is also known that in addition to mutations in
the 23S rRNA gene, other mechanisms are important in
CLR resistance in vivo, in particular an active multidrug
efflux mechanism of H. pylori [11].Conclusions
Twenty-six CLR-resistant strains were examined. The
conserved region of the H. pylori 23S rRNA gene was
checked for mutations. In addition, site-directed mutagen-
esis was performed in four CLR-susceptible H. pylori iso-
lates. The data show that a mutation at position A2143G
in 100% of the in vitro transformed strains leads to a syn-
ergistic effect between clarithromycin and amoxicillin,
whereas a mutation at position at A2142G has no effect
in vitro.
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